ICU Medical (NASDAQ:ICUI) Coverage Initiated at KeyCorp

Investment analysts at KeyCorp started coverage on shares of ICU Medical (NASDAQ:ICUIGet Free Report) in a research report issued on Tuesday, Benzinga reports. The firm set an “overweight” rating and a $134.00 price target on the medical instruments supplier’s stock. KeyCorp’s price target indicates a potential upside of 38.43% from the company’s current price.

A number of other research analysts also recently issued reports on the stock. TheStreet downgraded shares of ICU Medical from a “c-” rating to a “d+” rating in a research report on Tuesday, October 10th. CL King started coverage on ICU Medical in a research note on Thursday, December 14th. They issued a “buy” rating and a $110.00 target price for the company. One investment analyst has rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, ICU Medical presently has a consensus rating of “Moderate Buy” and an average price target of $122.00.

Read Our Latest Stock Analysis on ICU Medical

ICU Medical Stock Performance

Shares of ICUI stock opened at $96.80 on Tuesday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.99 and a current ratio of 2.63. The stock has a market capitalization of $2.34 billion, a price-to-earnings ratio of -82.74 and a beta of 0.65. ICU Medical has a one year low of $78.28 and a one year high of $212.43. The company’s 50-day simple moving average is $94.71 and its 200-day simple moving average is $112.53.

ICU Medical (NASDAQ:ICUIGet Free Report) last issued its earnings results on Monday, November 6th. The medical instruments supplier reported $1.23 EPS for the quarter, topping the consensus estimate of $0.94 by $0.29. The company had revenue of $553.31 million during the quarter, compared to analyst estimates of $554.00 million. ICU Medical had a positive return on equity of 6.53% and a negative net margin of 1.25%. Equities analysts anticipate that ICU Medical will post 5.07 earnings per share for the current fiscal year.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, VP Daniel Woolson sold 1,729 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $88.03, for a total value of $152,203.87. Following the sale, the vice president now owns 9,877 shares in the company, valued at $869,472.31. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ICU Medical

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP grew its holdings in ICU Medical by 71.6% during the first quarter. Wellington Management Group LLP now owns 1,516,089 shares of the medical instruments supplier’s stock worth $337,542,000 after acquiring an additional 632,609 shares during the period. FMR LLC grew its holdings in shares of ICU Medical by 89.9% during the third quarter. FMR LLC now owns 1,124,995 shares of the medical instruments supplier’s stock valued at $133,886,000 after buying an additional 532,483 shares in the last quarter. Morgan Stanley lifted its position in shares of ICU Medical by 233.5% in the fourth quarter. Morgan Stanley now owns 679,912 shares of the medical instruments supplier’s stock worth $107,073,000 after purchasing an additional 476,012 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its stake in ICU Medical by 59.2% in the third quarter. Fuller & Thaler Asset Management Inc. now owns 1,015,006 shares of the medical instruments supplier’s stock valued at $120,796,000 after purchasing an additional 377,532 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in ICU Medical by 8.8% during the first quarter. Vanguard Group Inc. now owns 2,122,104 shares of the medical instruments supplier’s stock valued at $472,466,000 after acquiring an additional 171,851 shares in the last quarter. 91.49% of the stock is currently owned by institutional investors.

ICU Medical Company Profile

(Get Free Report)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; and ClearGuard HD, that maintains hemodialysis catheters.

Featured Stories

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with's FREE daily email newsletter.